Search - tctmd.com

Displaying 261 - 280 of 707

Sort: Relevancy | Date

News Opinion CV Team Dispatch

April 2022 News Roundup

L.A. McKeown

April 01, 2022

News Daily News

Clopidogrel Superior to ‘Divine’ Aspirin Monotherapy in Secondary Prevention

Michael O'Riordan

March 30, 2022

More Evidence Links Breast Arterial Calcification and CVD Risk

News Daily News

Aortic Valve Replacement: What’s on the Wish List for Future Devices?

Shelley Wood

March 14, 2022

News Daily News

Guideline-Directed Therapies Underused in Frail HF Patients

L.A. McKeown

March 11, 2022

News Daily News

Recurrent Stroke Risk Lower With More Intense LDL-Lowering: Meta-analysis

Yael L. Maxwell

March 01, 2022

News Daily News

What Can Lp(a) Add to CAC for ASCVD Risk Prediction? New Insights

Yael L. Maxwell

February 22, 2022

News Daily News

Statin Intolerance Overestimated—Only ‘Small Number’ Get Side Effects: Meta-analysis

Michael O'Riordan

February 18, 2022

News Daily News

Icosapent Ethyl Cost-effective Compared With Standard Care: REDUCE-IT

Yael L. Maxwell

February 17, 2022

News Daily News

Study Touts Benefits of Exercise as Primary CVD Prevention in Older Adults

L.A. McKeown

February 15, 2022

News Daily News

Poor Prepregnancy Cardiometabolic Health Observed Across the US

Yael L. Maxwell

February 14, 2022

News Daily News

Absence of CAC May be Protective Even in Patients With Very High Cholesterol

Michael O'Riordan

February 14, 2022

News Daily News

Even Less-Severe COVID-19 Can Have Long-term CV Effects

Caitlin E. Cox

February 10, 2022

News Daily News

Yet Another US Report Shows Stalled Progress Against CHD

Caitlin E. Cox

January 19, 2022

News Daily News

As US Diabetes Rates Soar, AHA Urges CV Risk Factor Control

Caitlin E. Cox

January 10, 2022

News Daily News

Statins in Pregnancy Don’t Lead to Congenital Anomalies: Cohort Study

Yael L. Maxwell

January 03, 2022

News Daily News

Apixaban Appears Safer, More Effective Than Rivaroxaban in Medicare Study

Todd Neale

December 27, 2021

News Daily News

FDA Approves Inclisiran, a Twice-Yearly Injection to Lower LDL Levels

Michael O'Riordan

December 22, 2021

News Daily News

PASCAL Pinpoints Patients With Strokes Causally Related to PFO

Yael L. Maxwell

December 20, 2021

News Daily News

Risk Factors Still Matter for Patients With Zero CAC Score: MESA

Yael L. Maxwell

December 14, 2021

Advertisement

April 2022 News Roundup

Clopidogrel Superior to ‘Divine’ Aspirin Monotherapy in Secondary Prevention

More Evidence Links Breast Arterial Calcification and CVD Risk

Aortic Valve Replacement: What’s on the Wish List for Future Devices?

Guideline-Directed Therapies Underused in Frail HF Patients

Recurrent Stroke Risk Lower With More Intense LDL-Lowering: Meta-analysis

What Can Lp(a) Add to CAC for ASCVD Risk Prediction? New Insights

Statin Intolerance Overestimated—Only ‘Small Number’ Get Side Effects: Meta-analysis

Icosapent Ethyl Cost-effective Compared With Standard Care: REDUCE-IT

Study Touts Benefits of Exercise as Primary CVD Prevention in Older Adults

Poor Prepregnancy Cardiometabolic Health Observed Across the US

Absence of CAC May be Protective Even in Patients With Very High Cholesterol

Even Less-Severe COVID-19 Can Have Long-term CV Effects

Yet Another US Report Shows Stalled Progress Against CHD

As US Diabetes Rates Soar, AHA Urges CV Risk Factor Control

Statins in Pregnancy Don’t Lead to Congenital Anomalies: Cohort Study

Apixaban Appears Safer, More Effective Than Rivaroxaban in Medicare Study

FDA Approves Inclisiran, a Twice-Yearly Injection to Lower LDL Levels

PASCAL Pinpoints Patients With Strokes Causally Related to PFO

Risk Factors Still Matter for Patients With Zero CAC Score: MESA

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content